TY - JOUR
T1 - Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides
AU - Harbour, Victoria
AU - Casillas, Candice
AU - Siddiqui, Zain
AU - Sarkar, Biplab
AU - Sanyal, Sreya
AU - Nguyen, Peter
AU - Kim, Ka Kyung
AU - Roy, Abhishek
AU - Iglesias-Montoro, Patricia
AU - Patel, Saloni
AU - Podlaski, Frank
AU - Tolias, Peter
AU - Windsor, William
AU - Kumar, Vivek
N1 - Publisher Copyright:
© 2020 ACS. All rights reserved.
PY - 2020/12/21
Y1 - 2020/12/21
N2 - High levels of serum low-density lipoprotein (LDL) cholesterol contribute to atherosclerosis, a key risk factor of cardiovascular diseases. PCSK9 is a circulatory enzyme that downregulates expression of hepatic LDL receptors, concomitantly increasing serum LDL-C. This work investigates a small, self-assembling peptide, EPep2-8, as a peptide inhibitor of PCSK9. EPep2-8 is a multidomain peptide comprising a self-assembling domain, E2, conjugated to a bioactive domain, Pep2-8, previously shown to inhibit PCSK9. The E2 domain facilitates self-assembly of EPep2-8 into long, nanofibrous polymers with an underlying supramolecular β-sheet secondary structure. Intermolecular interactions between nanofibers drive EPep2-8 to form a thixotropic and cytocompatible hydrogel in aqueous and charge-neutral solutions. These properties enable EPep2-8 to be delivered as an in situ depot for regulation of lipoprotein homeostasis. In surface plasmon resonance studies, EPep2-8 bound specifically to PCSK9 with an apparent, noncovalent, and irreversible dissociation, significantly improving the binding affinity of Pep2-8 alone (KD = 667 ± 48 nM). Increased binding affinity of EPep2-8 is primarily due to the superstoichiometric interaction of the peptide with PCSK9. Promisingly, EPep2-8 retains bioactivity in vitro, engendering dose-dependent uptake of LDL-C in hepatocytes. This mechanism of self-assembly on a target site may be a simple method to improve the affinity of peptide inhibitors.
AB - High levels of serum low-density lipoprotein (LDL) cholesterol contribute to atherosclerosis, a key risk factor of cardiovascular diseases. PCSK9 is a circulatory enzyme that downregulates expression of hepatic LDL receptors, concomitantly increasing serum LDL-C. This work investigates a small, self-assembling peptide, EPep2-8, as a peptide inhibitor of PCSK9. EPep2-8 is a multidomain peptide comprising a self-assembling domain, E2, conjugated to a bioactive domain, Pep2-8, previously shown to inhibit PCSK9. The E2 domain facilitates self-assembly of EPep2-8 into long, nanofibrous polymers with an underlying supramolecular β-sheet secondary structure. Intermolecular interactions between nanofibers drive EPep2-8 to form a thixotropic and cytocompatible hydrogel in aqueous and charge-neutral solutions. These properties enable EPep2-8 to be delivered as an in situ depot for regulation of lipoprotein homeostasis. In surface plasmon resonance studies, EPep2-8 bound specifically to PCSK9 with an apparent, noncovalent, and irreversible dissociation, significantly improving the binding affinity of Pep2-8 alone (KD = 667 ± 48 nM). Increased binding affinity of EPep2-8 is primarily due to the superstoichiometric interaction of the peptide with PCSK9. Promisingly, EPep2-8 retains bioactivity in vitro, engendering dose-dependent uptake of LDL-C in hepatocytes. This mechanism of self-assembly on a target site may be a simple method to improve the affinity of peptide inhibitors.
KW - LDL
KW - PCSK9
KW - cholesterol metabolism
KW - peptide amphiphiles
KW - self-assembly
UR - http://www.scopus.com/inward/record.url?scp=85097870356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097870356&partnerID=8YFLogxK
U2 - 10.1021/acsabm.0c01229
DO - 10.1021/acsabm.0c01229
M3 - Article
AN - SCOPUS:85097870356
SN - 2576-6422
VL - 3
SP - 8978
EP - 8988
JO - ACS Applied Bio Materials
JF - ACS Applied Bio Materials
IS - 12
ER -